Brexafemme (Ibrexafungerp)

Brexafemme (Ibrexafungerp)

Brexafemme

Ibrexafungerp

Tablets: 150 mg

Scynexis, Inc.

Medical Use

Brexafemme is an oral tablet containing ibrexafungerp citrate, a triterpenoid antifungal agent. It is commonly prescribed for adults and post-menarchal pediatric females to:

  • Treat vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection.
  • Reduce the recurrence of vulvovaginal candidiasis (RVVC).

Dosage Instructions: Brexafemme tablets can be taken with or without food, following your doctor’s instructions. The typical dosage is two tablets (300 mg) taken orally in the morning and two tablets (300 mg) taken orally in the evening, ideally about 12 hours apart.

For Treating VVC: The recommended dosage for adults and post-menarchal pediatric females is 300 mg (two 150 mg Brexafemme tablets) taken approximately 12 hours apart (morning and evening) for one day, totaling 600 mg (four 150 mg tablets) for the day.

For Reducing RVVC: The recommended dosage for adults and post-menarchal pediatric females is 300 mg (two 150 mg Brexafemme tablets) taken approximately 12 hours apart (morning and evening) for one day, totaling 600 mg (four 150 mg tablets) per day, administered monthly for six months.